156 related articles for article (PubMed ID: 11082700)
1. [Natural organic compounds that affect to microtubule functions: syntheses and structure-activity relationships of combretastatins, curacin A and their analogs as the colchicine-site ligands on tubulin].
Iwasaki S; Shirai R
Yakugaku Zasshi; 2000 Oct; 120(10):875-89. PubMed ID: 11082700
[TBL] [Abstract][Full Text] [Related]
2. Natural organic compounds that affect to microtubule functions.
Iwasaki S
Yakugaku Zasshi; 1998 Apr; 118(4):112-26. PubMed ID: 9564789
[TBL] [Abstract][Full Text] [Related]
3. Characterization of the interaction of the marine cyanobacterial natural product curacin A with the colchicine site of tubulin and initial structure-activity studies with analogues.
Blokhin AV; Yoo HD; Geralds RS; Nagle DG; Gerwick WH; Hamel E
Mol Pharmacol; 1995 Sep; 48(3):523-31. PubMed ID: 7565634
[TBL] [Abstract][Full Text] [Related]
4. Structure-activity analysis of the interaction of curacin A, the potent colchicine site antimitotic agent, with tubulin and effects of analogs on the growth of MCF-7 breast cancer cells.
Verdier-Pinard P; Lai JY; Yoo HD; Yu J; Marquez B; Nagle DG; Nambu M; White JD; Falck JR; Gerwick WH; Day BW; Hamel E
Mol Pharmacol; 1998 Jan; 53(1):62-76. PubMed ID: 9443933
[TBL] [Abstract][Full Text] [Related]
5. Antimitotic natural products combretastatin A-4 and combretastatin A-2: studies on the mechanism of their inhibition of the binding of colchicine to tubulin.
Lin CM; Ho HH; Pettit GR; Hamel E
Biochemistry; 1989 Aug; 28(17):6984-91. PubMed ID: 2819042
[TBL] [Abstract][Full Text] [Related]
6. Interactions of tubulin with potent natural and synthetic analogs of the antimitotic agent combretastatin: a structure-activity study.
Lin CM; Singh SB; Chu PS; Dempcy RO; Schmidt JM; Pettit GR; Hamel E
Mol Pharmacol; 1988 Aug; 34(2):200-8. PubMed ID: 3412321
[TBL] [Abstract][Full Text] [Related]
7. Development of combretastatins as potent tubulin polymerization inhibitors.
Bukhari SNA; Kumar GB; Revankar HM; Qin HL
Bioorg Chem; 2017 Jun; 72():130-147. PubMed ID: 28460355
[TBL] [Abstract][Full Text] [Related]
8. Podophyllotoxin, steganacin and combretastatin: natural products that bind at the colchicine site of tubulin.
Sackett DL
Pharmacol Ther; 1993 Aug; 59(2):163-228. PubMed ID: 8278462
[TBL] [Abstract][Full Text] [Related]
9. Chemistry and biology of curacin A.
Wipf P; Reeves JT; Day BW
Curr Pharm Des; 2004; 10(12):1417-37. PubMed ID: 15134491
[TBL] [Abstract][Full Text] [Related]
10. Isolation, structure, and synthesis of combretastatins A-1 and B-1, potent new inhibitors of microtubule assembly, derived from Combretum caffrum.
Pettit GR; Singh SB; Niven ML; Hamel E; Schmidt JM
J Nat Prod; 1987; 50(1):119-31. PubMed ID: 3598594
[TBL] [Abstract][Full Text] [Related]
11. Isolation, structure, synthesis, and antimitotic properties of combretastatins B-3 and B-4 from Combretum caffrum.
Pettit GR; Singh SB; Schmidt JM; Niven ML; Hamel E; Lin CM
J Nat Prod; 1988; 51(3):517-27. PubMed ID: 3404149
[TBL] [Abstract][Full Text] [Related]
12. Evaluation of the cytotoxic mechanism mediated by baccatin III, the synthetic precursor of taxol.
Pengsuparp T; Kingston DG; Neidigh KA; Cordell GA; Pezzuto JM
Chem Biol Interact; 1996 Aug; 101(2):103-14. PubMed ID: 8760392
[TBL] [Abstract][Full Text] [Related]
13. The interaction of the B-ring of colchicine with alpha-tubulin: a novel footprinting approach.
Chaudhuri AR; Seetharamalu P; Schwarz PM; Hausheer FH; Ludueña RF
J Mol Biol; 2000 Nov; 303(5):679-92. PubMed ID: 11061968
[TBL] [Abstract][Full Text] [Related]
14. Discovery, synthesis, activities, structure-activity relationships, and clinical development of combretastatins and analogs as anticancer drugs. A comprehensive review.
Singh SB
Nat Prod Rep; 2024 Feb; 41(2):298-322. PubMed ID: 38009216
[TBL] [Abstract][Full Text] [Related]
15. Combretastatin-like chalcones as inhibitors of microtubule polymerisation. Part 2: Structure-based discovery of alpha-aryl chalcones.
Ducki S; Mackenzie G; Greedy B; Armitage S; Chabert JF; Bennett E; Nettles J; Snyder JP; Lawrence NJ
Bioorg Med Chem; 2009 Nov; 17(22):7711-22. PubMed ID: 19837594
[TBL] [Abstract][Full Text] [Related]
16. Synthesis and antimicrotubule activity of combretatropone derivatives.
Janik ME; Bane SL
Bioorg Med Chem; 2002 Jun; 10(6):1895-903. PubMed ID: 11937347
[TBL] [Abstract][Full Text] [Related]
17. Biosynthesis of radiolabeled curacin A and its rapid and apparently irreversible binding to the colchicine site of tubulin.
Verdier-Pinard P; Sitachitta N; Rossi JV; Sackett DL; Gerwick WH; Hamel E
Arch Biochem Biophys; 1999 Oct; 370(1):51-8. PubMed ID: 10496976
[TBL] [Abstract][Full Text] [Related]
18. A common pharmacophore for a diverse set of colchicine site inhibitors using a structure-based approach.
Nguyen TL; McGrath C; Hermone AR; Burnett JC; Zaharevitz DW; Day BW; Wipf P; Hamel E; Gussio R
J Med Chem; 2005 Sep; 48(19):6107-16. PubMed ID: 16162011
[TBL] [Abstract][Full Text] [Related]
19. Microtubulin binding sites as target for developing anticancer agents.
Islam MN; Iskander MN
Mini Rev Med Chem; 2004 Dec; 4(10):1077-104. PubMed ID: 15579115
[TBL] [Abstract][Full Text] [Related]
20. Anti-tubulin agents of natural origin: Targeting taxol, vinca, and colchicine binding domains.
Naaz F; Haider MR; Shafi S; Yar MS
Eur J Med Chem; 2019 Jun; 171():310-331. PubMed ID: 30953881
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
